PARP Inhibitors Market
Market Insights on PARP Inhibitors covering sales outlook, demand forecast & up-to-date key trends
PARP Inhibitors by Drug Type (Olaparib, Niraparib, Rucaparib, Talazoparib), Indication (Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer), Distribution Channel (Hospital Pharmacies, Retail Pharmacies,) & Region for 2022-2026
PARP Inhibitors Outlook – 2022-2026
[179 Pages Report] The global Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors Market is estimated to top US$ 5.51 Bn by 2022. Surging demand for advanced targeted therapy for the treatment of chronic diseases such as cancer is augmenting the growth in the market.
|
Attribute |
Details |
|
PARP Inhibitors Market Estimated Size in 2022 |
US$ 5.51 Bn |
|
PARP Inhibitors Market Projected Size in 2026 |
US$ 8.43 Bn |
|
PARP Inhibitors Market Historical CAGR (2014-2021) |
90.4% |
|
PARP Inhibitors Market Value-based CAGR (2022-2026) |
11.2% |
As per Future Market Insights (FMI), the demand in the PARP inhibitors market is expected to surpass US$ 8.43 Bn, growing at an impressive CAGR of 11.2% during the forecast period 2022-2026.
Among drug type verticals, olaparib is estimated to remain the most sought-after drug in the global market, accounting for more than 62.9% of the PARP inhibitors sales by 2022. FMI states that the PARP inhibitors are estimated to account for over 28.5% of the revenue share in the global cytotoxic toxic drugs market.
Let us know your requirement to get
100% FREE customization
How The Market Progressed Till June 2022?
|
Particulars |
Details |
|
H1, 2021 |
14.56% |
|
H1, 2022 Projected |
10.84% |
|
H1, 2022 Outlook |
9.54% |
|
BPS Change - H1, 2022 (O) – H1, 2022 (P) |
(-) 130 ↓ |
|
BPS Change – H1, 2022 (O) – H1, 2021 |
(-) 502 ↓ |
The variation between the BPS values observed within this market in H1, 2022 - outlook over H1, 2022 projected reflects a decline of 130 units. A steep decline in BPS growth in H1-2022 over H1-2021 by 502 Basis Point Share (BPS) is demonstrated by the PARP inhibitors market.
The market decline observed through the drop in the BPS values is addressed by the reported haematological toxicities induced by the PARP inhibitors, and the adverse effects associated with the therapy. Moreover, PARP inhibitor therapy has been reported to pose a great financial burden on patients, thus lowering its adherence rate, and consequently, the sales adoption.
The global PARP inhibitors market is subject to drug safety guidelines, and therapeutic reimbursements, in accordance to the macro and industrial scale factors.
The key developments in the market include the identification of new target sites for the PARP inhibitor drugs, as well as their potential for application in several disease indications. The market is highly influenced by stringent policies for regulation and licensing of drugs and molecular entities used for clinical purposes.
2014-2021 PARP Inhibitors Market Outlook in Comparison to 2022-2026 Growth Forecast
PARP inhibitors are a group of pharmacological inhibitors of the enzyme, poly ADP ribose polymerase. These inhibitors block PARP enzymes, preventing healthy cells from DNA damage and assist in repairing the damaged part of DNA in cancerous cells.
According to a study by Penn Medicine Organization, use of PARP inhibitors have showcased impressive cancer patient treatment outcome, especially when combined with other therapies such as radiation and chemo.
Driven by this, PARP inhibitors has registered a robust surge in demand over the last assessment year, exhibiting growth at a staggering CAGR of 90.4% between 2014 and 2021.
Thus, growing PARP inhibitors usage for increasing cytotoxicity in cancer patients to eliminate cancer cells in BRCA-mutation cancer cell lines and inhibiting DNA damage repair when combined with chemotherapies is propelling the demand in the market. This is expected to assist the global PARP inhibitors market to total US$ 8.43 Bn by the end of 2026.
How is the Rising Burden of Cancer Creating Growth Avenues for the PARP Inhibitors Market?
Prevalence of fatal diseases such as cancer is rapidly increasing worldwide due to growing obesity and increasing smoking and alcohol consumption, resulting in propelling the demand for associated treatments.
According to a report by the World Health Organization (WHO), cancer is a leading cause of death across the world, accounting for approximately 10 million deaths in the year 2020. Out of which nearly 685,000 deaths were caused due to breast cancer.
PARP inhibitors possess the unique ability to improve progression-free survival and repair DNA damage in cells. Attributed to this, these inhibitors are extensively being used for the treatment of various types of cancers such as ovarian and breast cancer. Hence, increasing burden of cancer is estimated to create lucrative sales opportunities for cancer therapeutics such as PARP inhibitors in the coming years.
As per FMI, the sales of PARP inhibitors are estimated to total US$ 5.51 Bn by 2022, accelerating at 11.2% CAGR over the forecast period 2022-2026.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow will Increasing Number of Cancer Awareness Campaigns Elevate the PARP Inhibitors Market Growth?
With increasing prevalence and fatalities due to breast, ovarian, prostate, and other cancers, governmental and non-governmental organizations are increasingly undertaking number of public awareness campaigns regarding early cancer diagnosis and treatment.
For instance, the Ministry of Health and Family Welfare has launched a National Programme for Prevention & Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS) to strengthen treatment infrastructure and spreads awareness regarding early diagnosis of non-communicable diseases such as cancer.
In addition to this, collaborative efforts by market players and research & academic institutes to curb cancer deaths are estimated to spur the sales of PARP inhibitors. Driven by this, the global PARP inhibitors market is expected to expand by 1.52x between 2022 and 2026.
Country-wise Analysis
What are the Factor Favoring U.S. PARP Inhibitors Growth?
“Growing Product Approvals by FDA to Bolster the Sales of Niraparib PARP Inhibitors”
The U.S. is estimated to continue dominating the North America PARP inhibitors during the forecast period 2022-2026.
As the demand for advanced cancer therapeutics such as PARP inhibitors continues to surge, leading regulatory bodies in the country are increasingly focusing on studying and granting approvals for new cancer treatment.
For instance, in 2020, the U.S. Food and Drug Administration (FDA) announced granting approval for new Niraparib PARP inhibitor monotherapy for first-line treatment for ovarian cancer. A multiplicity of such development and new product launches is anticipated to facilitate the sales of PARP inhibitors in the U.S. market.
Why is the Demand for PARP Inhibitors Surging in the India Market?
“Increasing Cases of Breast Cancer to Fuel the Demand for PARP Inhibitors”
India is forecast to emerge as a highly lucrative market for PARP inhibitors in South Asia between 2022 and 2026.
A significant rise in burden of breast cancer is being witnessed across India, creating strong demand for cancer diagnostics and treatment in the market. According to the Indian Council of Medical Research (ICMR), breast cancer is the most common type of cancer found in Indian women. In 2018, nearly 162,468 new cases and 87,090 fatalities due to breast cancer were reported across India.
As PARP inhibitors are increasingly being used in combination with other breast cancer treatments such as radiation and chemotherapies for repairing DNA damage post-exposure to ultraviolet (UV) radiation, rising prevalence of breast cancer is expected to favor the growth in the India market.
Why is the PARP Inhibitors Market in the U.K. Expanding at Rapid Pace?
“Growing Emphasis on Public Awareness Regarding Cancer to Propel the PARP Inhibitors Demand”
The U.K. is projected to account for a significant share in the Europe PARP inhibitors over the assessment period, reveals FMI.
Increasing government and non-government organizations’ emphasis on spreading public awareness regarding early diagnosis and treatment for cancer is the primary factor bolstering the sales of PARP inhibitors in the U.K. market.
For instance, Public Health England has launched a new campaign ‘Be Clear on Cancer,’ which focuses on improving early cancer diagnostics by spreading public awareness regarding cancer. In addition to this, the presence of favorable medical reimbursement policies in the U.K. is anticipated to bolster the demand for PARP inhibitors in the market.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-wise Insights
Why are Olaparib PARP Inhibitors Gaining Popularity in the Market?
“Olaparib to Remain the Most Preferred PARP Inhibitors Drug in the Market”
The olaparib segment is expected to register the fastest growth in the global PARP inhibitors market, accounting for more than 62.9% of the revenue share by the end of 2022.
Increasing product approvals and growing adoption of olaparib PARP inhibitors for the treatment of breast cancer, ovarian cancer, and pancreatic cancer is estimated to facilitate growth in the segment. Apart from this, the niraparib segment is estimated to exhibit robust growth, account for nearly 1/3rd of the PARP inhibitors sales through 2022.
Which Indication Segment will Register Robust Growth?
“Growing Adoption in Advanced First line Settings to Accelerate PARP indicator Sales”
On the basis of indication, the prostate cancer segment is anticipated to account for a significant share in the PARP indicator market through 2026, reveals FMI.
The leading factor favoring the growth in the market is growing burden of prostate cancer worldwide. According to the World Cancer Research Fund, prostate cancer is the 2nd most common type of cancer found in men and 4th most commonly occurring cancer overall.
In addition, increasing adoption of olaparib in advanced first-line settings for prostate cancer treatment is expected to spur the sales of PARP indicators in the segment.
Why are the Sales of PARP Inhibitors Rising in Retail Pharmacies Segment?
“Retail Pharmacies to Outrank Other Distribution Channels in the PARP indicator Market”
In terms of distribution channel, the global PARP indicator market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. FMI reveals that the retail pharmacies segment is forecast to account for the dominants share, creating an absolute dollar opportunity of US$ 4 Bn from 2022 to 2026.
Besides this, the online pharmacies segment is forecast to exhibit growth at a rapid CAGR through 2026. Increasing customer inclination towards using online platforms for purchasing medication and other medical accessories is projected to drive the sales of PARP indicators in the segment.
Competitive Landscape
Key companies in the global PARP indicator market are aiming at entering into collaboration, merger, acquisition, partnership and agreements with others players to develop new products for expanding their product portfilio. For instance,
- In May 2019, Clovis Oncology, Inc., American pharmaceutical company announced entering in a collaboration with two companies - Foundation Medicine Inc. and Bristol-Myers Squibb Company for initiating Phase II studies to evaluate in nivolumab combination with rucaparib in patients with endometrial ovarian cancer.
Scope of the Report
|
Attribute |
Details |
|
Forecast Period |
2022-2026 |
|
Historical Data Available for |
2014-2021 |
|
Market Analysis |
US$ Bn for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa |
|
Key Countries Covered |
US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Vietnam, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, South Africa |
|
Key Segments Covered |
Drug type, Indication, Distribution Channel, and Region |
|
Key Companies Profiled |
|
|
Report Coverage |
Market Forecast, brand share analysis, competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
|
Customization & Pricing |
Available upon Request |
PARP Inhibitors Market by Category
By Drug Type:
- Olaparib
- Niraparib
- Rucaparib
- Talazoparib
By Indication:
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer
- Pancreatic Cancer
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Latin America
- South Asia
- East Asia
- Oceania
- Middle East And Africa
Frequently Asked Questions
What is the current PARP inhibitors market value?
The PARP inhibitors market is expected to surpass a valuation of US$ 5.51 Bn in 2022.
At what rate did the sales of PARP inhibitors grow in the last assessment period?
The global PARP inhibitors market grew at a 90.4% CAGR over the past assessment period 2014-2021.
At what rate will PARP inhibitors market grow between 2022 and 2026?
The PARP inhibitors market is expected to register remarkable growth, expanding at 11.2% CAGR between 2022 and 2026.
Which is the most lucrative market for PARP inhibitors?
North America will emerge as the most lucrative market for PARP inhibitors between 2022 and 2026.
What is the East Asia PARP inhibitors market outlook?
South Asia PARP inhibitors market will hold a significant share over the assessment period 2022-2026.
Which drug type segment accounts for maximum PARP inhibitors sales?
In terms of drug type, the olaparib segment is expected to account for maximum sales in the global PARP inhibitors market through 2026.
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Key Market Trends 3.1. Key Trends Impacting The Market 4. Key Inclusions 4.1. Key Regulations 4.2. Pipeline Analysis 4.3. Epidemiology for Different Cancer, By Country 5. Global Market Demand (in Value or Size in US$ Mn) Analysis 2015-2021 and Forecast, 2022-2026 5.1. Historical Market Value (US$ Mn) Analysis, 2015-2021 5.2. Current and Future Market Value (US$ Mn) Projections, 2022-2026 5.2.1. Y-o-Y Growth Trend Analysis 5.2.2. Absolute $ Opportunity Analysis 6. Market Background 6.1. Macro-Economic Factors 6.2. Forecast Factors - Relevance & Impact 6.3. Market Dynamics 6.3.1. Drivers 6.3.2. Restraints 6.3.3. Opportunity Analysis 7. Global Market Analysis 2015-2021 and Forecast 2022-2026, by Drug Type 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2015-2021 7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Type, 2022-2026 7.3.1. Niraparib 7.3.2. Olaparib 7.3.3. Rucaparib 7.3.4. Talazoparib 7.4. Market Attractiveness Analysis By Drug Type 8. Global Market Analysis 2015-2021 and Forecast 2022-2026, by Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2021 - 2021 8.3.1. Ovarian Cancer 8.3.2. Breast Cancer 8.3.3. Prostate Cancer 8.3.4. Pancreatic Cancer 8.4. Market Attractiveness Analysis By Indication 9. Global Market Analysis 2015-2021 and Forecast 2022-2026, by Distribution Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015-2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021 - 2021 9.3.1. Hospital Pharmacies 9.3.2. Retail Pharmacies 9.3.3. Online Pharmacies 9.4. Market Attractiveness Analysis By Distribution Channel 10. Global Market Analysis 2015-2021 and Forecast 2022-2026, by Region 10.1. Introduction 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021 10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021 - 2021 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. South Asia 10.3.5. East Asia 10.3.6. Oceania 10.3.7. Middle East and Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Market Analysis 2015-2021 and Forecast 2022-2026 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 11.3.1. By Country 11.3.1.1. U.S. 11.3.1.2. Canada 11.3.2. By Drug Type 11.3.3. By Indication 11.3.4. By Distribution Channel 11.4. Market Attractiveness Analysis 11.5. Key Market Participants - Intensity Mapping 11.6. Drivers and Restraints - Impact Analysis 12. Latin America Market Analysis 2015-2021 and Forecast 2022-2026 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 12.3.1. By Country 12.3.1.1. Brazil 12.3.1.2. Mexico 12.3.1.3. Argentina 12.3.1.4. Rest of Latin America 12.3.2. By Drug Type 12.3.3. By Indication 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.5. Key Market Participants - Intensity Mapping 12.6. Drivers and Restraints - Impact Analysis 13. Europe Market Analysis 2015-2021 and Forecast 2022-2026 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. Italy 13.3.1.3. France 13.3.1.4. U.K. 13.3.1.5. Spain 13.3.1.6. Rest of Europe 13.3.2. By Drug Type 13.3.3. By Indication 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 14. South Asia Market Analysis 2015-2021 and Forecast 2022-2026 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 14.3.1. By Country 14.3.1.1. India 14.3.1.2. Rest of South Asia 14.3.2. By Drug Type 14.3.3. By Indication 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 15. East Asia Market Analysis 2015-2021 and Forecast 2022-2026 15.1. Introduction 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Drug Type 15.3.3. By Indication 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 16. Oceania Market Analysis 2015-2021 and Forecast 2022-2026 16.1. Introduction 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 16.3.1. By Country 16.3.1.1. Australia 16.3.1.2. New Zealand 16.3.2. By Drug Type 16.3.3. By Indication 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 17. Middle East and Africa Market Analysis 2015-2021 and Forecast 2022-2026 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021 17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026 17.3.1. By Country 17.3.1.1. Turkey 17.3.1.2. Rest of Middle East and Africa 17.3.2. By Drug Type 17.3.3. By Indication 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 18. Market Structure Analysis 18.1. Market Analysis by Tier of Companies (Tissue Diagnostics ) 18.2. Market Concentration 18.3. Market Share Analysis of Top Players 18.4. Market Presence Analysis 18.4.1. By Regional Footprint of Players 18.4.2. Product Footprint by Players 18.4.3. Channel Footprint by Players 19. Competition Analysis 19.1. Competition Dashboard 19.2. Pricing Analysis by Competition 19.3. Competition Benchmarking 19.4. Competition Deep Dive 19.4.1. Pfizer Inc. 19.4.1.1. Overview 19.4.1.2. Product Portfolio 19.4.1.3. Sales Footprint 19.4.1.4. Analyst commentary 19.4.2. AstraZeneca 19.4.2.1. Overview 19.4.2.2. Product Portfolio 19.4.2.3. Sales Footprint 19.4.2.4. Analyst commentary 19.4.3. Merck & Co. Inc. 19.4.3.1. Overview 19.4.3.2. Product Portfolio 19.4.3.3. Sales Footprint 19.4.3.4. Analyst commentary 19.4.4. GlaxoSmithKline Plc. (TESARO INC.) 19.4.4.1. Overview 19.4.4.2. Product Portfolio 19.4.4.3. Sales Footprint 19.4.4.4. Analyst commentary 19.4.5. Clovis Oncology 19.4.5.1. Overview 19.4.5.2. Product Portfolio 19.4.5.3. Sales Footprint 19.4.5.4. Analyst commentary 19.4.6. BeiGene 19.4.6.1. Overview 19.4.6.2. Product Portfolio 19.4.6.3. Sales Footprint 19.4.6.4. Analyst commentary 19.4.7. Jiangsu Hengrui Medicine Co. 19.4.7.1. Overview 19.4.7.2. Product Portfolio 19.4.7.3. Sales Footprint 19.4.7.4. Analyst commentary 19.4.8. Oncology Venture AB 19.4.8.1. Overview 19.4.8.2. Product Portfolio 19.4.8.3. Sales Footprint 19.4.8.4. Analyst commentary 20. Assumptions and Acronyms Used 21. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01A: Funding by Research Areas 2021 (US$ Millions) Table 01B: Funding by Research Areas 2021 (US$ Millions) Table 02: Global Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Drug Type Table 03: Global Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Indication Table 04: Global Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Distribution Channel Table 05: Global Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Region Table 06: North America Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country Table 07: North America Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type Table 08: North America Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication Table 09: North America Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel Table 10: Latin America Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country Table 11: Latin America Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type Table 12: Latin America Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication Table 13: Latin America Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel Table 14: Europe Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country Table 15: Europe Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type Table 16: Europe Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication Table 17: Europe Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel Table 18: South Asia Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country Table 19: South Asia Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type Table 20: South Asia Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication Table 21: South Asia Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel Table 22: East Asia Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country Table 23: East Asia Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type Table 24: East Asia Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication Table 25: East Asia Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel Table 26: Oceania Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country Table 27: Oceania Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type Table 28: Oceania Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication Table 29: Oceania Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel Table 30: MEA Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country Table 31: MEA Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type Table 32: MEA Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication Table 33: MEA Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Historical Market Size and Y-o-Y, 2015–2021 Figure 02: Global Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2026 Figure 03: Global Market Absolute $ Opportunity, 2015–2026 Figure 04: Global Market Share Analysis (%) By Drug Type, 2022 & 2026 Figure 05: Global Market Y-o-Y Growth (%) By Drug Type, 2022–2026 Figure 06: Global Market Attractiveness Analysis, By Drug Type Figure 07: Global Market Share Analysis (%) By Indication, 2022 & 2026 Figure 08: Global Market Y-o-Y Growth (%) By Indication, 2022–2026 Figure 09: Global Market Attractiveness Analysis, By Indication Figure 10: Global Market Share Analysis (%) By Distribution Channel, 2022 & 2026 Figure 11: Global Market Y-o-Y Growth (%) By Distribution Channel, 2022–2026 Figure 12: Global Market Attractiveness Analysis, By Distribution Channel Figure 13: Global Market Share Analysis (%) By Region, 2022 & 2026 Figure 14: Global Market Y-o-Y Growth (%) By Region, 2022–2026 Figure 15: Global Market Attractiveness Analysis, By Region Figure 16: North America Market Size (US$ Mn), 2015-2021 Figure 17: North America Market Size (US$) & Y-o-Y Growth (%), 2022–2026 Figure 18: North America Market Analysis by Country – 2022 & 2026 Figure 19: North America Market Y-o-Y Growth Projections by Country, 2022-2026 Figure 20: North America Market Attractiveness Analysis by Country, 2022-2026 Figure 21: North America Market Analysis by Drug Type –2022 & 2026 Figure 22: North America Market Y-o-Y Growth Projections by Drug Type, 2022-2026 Figure 23: North America Market Attractiveness Analysis by Drug Type, 2022-2026 Figure 24: North America Market Analysis by Indication –2022 & 2026 Figure 25: North America Market Y-o-Y Growth Projections by Indication, 2022-2026 Figure 26: North America Market Attractiveness Analysis by Indication, 2022-2026 Figure 27: North America Market Analysis by Distribution Channel –2022 & 2026 Figure 28: North America Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026 Figure 29: North America Market Attractiveness Analysis by Distribution Channel, 2022-2026 Figure 30: Latin America Market Size (US$ Mn), 2015-2021 Figure 31: Latin America Market Size (US$) & Y-o-Y Growth (%), 2022–2026 Figure 32: Latin America Market Analysis by Country – 2022 & 2026 Figure 33: Latin America Market Y-o-Y Growth Projections by Country, 2022-2026 Figure 34: Latin America Market Attractiveness Analysis by Country, 2022-2026 Figure 35: Latin America Market Analysis by Drug Type –2022 & 2026 Figure 36: Latin America Market Y-o-Y Growth Projections by Drug Type, 2022-2026 Figure 37: Latin America Market Attractiveness Analysis by Drug Type, 2022-2026 Figure 38: Latin America Market Analysis by Indication –2022 & 2026 Figure 39: Latin America Market Y-o-Y Growth Projections by Indication, 2022-2026 Figure 40: Latin America Market Attractiveness Analysis by Indication, 2022-2026 Figure 41: Latin America Market Analysis by Distribution Channel –2022 & 2026 Figure 42: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026 Figure 43: Latin America Market Attractiveness Analysis by Distribution Channel, 2022-2026 Figure 44: Europe Market Size (US$ Mn), 2015-2021 Figure 45: Europe Market Size (US$) & Y-o-Y Growth (%), 2022–2026 Figure 46: Europe Market Analysis by Country – 2022 & 2026 Figure 47: Europe Market Y-o-Y Growth Projections by Country, 2022-2026 Figure 48: Europe Market Attractiveness Analysis by Country, 2022-2026 Figure 49: Europe Market Analysis by Drug Type –2022 & 2026 Figure 50: Europe Market Y-o-Y Growth Projections by Drug Type, 2022-2026 Figure 51: Europe Market Attractiveness Analysis by Drug Type, 2022-2026 Figure 52: Europe Market Analysis by Indication –2022 & 2026 Figure 53: Europe Market Y-o-Y Growth Projections by Indication, 2022-2026 Figure 54: Europe Market Attractiveness Analysis by Indication, 2022-2026 Figure 55: Europe Market Analysis by Distribution Channel –2022 & 2026 Figure 56: Europe Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026 Figure 57: Europe Market Attractiveness Analysis by Distribution Channel, 2022-2026 Figure 58: South Asia Market Size (US$ Mn), 2015-2021 Figure 59: South Asia Market Size (US$) & Y-o-Y Growth (%), 2022–2026 Figure 60: South Asia Market Analysis by Country – 2022 & 2026 Figure 61: South Asia Market Y-o-Y Growth Projections by Country, 2022-2026 Figure 62: South Asia Market Attractiveness Analysis by Country, 2022-2026 Figure 63: South Asia Market Analysis by Drug Type –2022 & 2026 Figure 64: South Asia Market Y-o-Y Growth Projections by Drug Type, 2022-2026 Figure 65: South Asia Market Attractiveness Analysis by Drug Type, 2022-2026 Figure 66: South Asia Market Analysis by Indication –2022 & 2026 Figure 67: South Asia Market Y-o-Y Growth Projections by Indication, 2022-2026 Figure 68: South Asia Market Attractiveness Analysis by Indication, 2022-2026 Figure 69: South Asia Market Analysis by Distribution Channel –2022 & 2026 Figure 70: South Asia Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026 Figure 71: South Asia Market Attractiveness Analysis by Distribution Channel, 2022-2026 Figure 72: East Asia Market Size (US$ Mn), 2015-2021 Figure 73: East Asia Market Size (US$) & Y-o-Y Growth (%), 2022–2026 Figure 74: East Asia Market Analysis by Country – 2022 & 2026 Figure 75: East Asia Market Y-o-Y Growth Projections by Country, 2022-2026 Figure 76: East Asia Market Attractiveness Analysis by Country, 2022-2026 Figure 77: East Asia Market Analysis by Drug Type –2022 & 2026 Figure 78: East Asia Market Y-o-Y Growth Projections by Drug Type, 2022-2026 Figure 79: East Asia Market Attractiveness Analysis by Drug Type, 2022-2026 Figure 80: East Asia Market Analysis by Indication –2022 & 2026 Figure 81: East Asia Market Y-o-Y Growth Projections by Indication, 2022-2026 Figure 82: East Asia Market Attractiveness Analysis by Indication, 2022-2026 Figure 83: East Asia Market Analysis by Distribution Channel –2022 & 2026 Figure 84: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026 Figure 85: East Asia Market Attractiveness Analysis by Distribution Channel, 2022-2026 Figure 86: Oceania Market Size (US$ Mn), 2015-2021 Figure 87: Oceania Market Size (US$) & Y-o-Y Growth (%), 2022–2026 Figure 88: Oceania Market Analysis by Country – 2022 & 2026 Figure 89: Oceania Market Y-o-Y Growth Projections by Country, 2022-2026 Figure 90: Oceania Market Attractiveness Analysis by Country, 2022-2026 Figure 91: Oceania Market Analysis by Drug Type –2022 & 2026 Figure 92: Oceania Market Y-o-Y Growth Projections by Drug Type, 2022-2026 Figure 93: Oceania Market Attractiveness Analysis by Drug Type, 2022-2026 Figure 94: Oceania Market Analysis by Indication –2022 & 2026 Figure 95: Oceania Market Y-o-Y Growth Projections by Indication, 2022-2026 Figure 96: Oceania Market Attractiveness Analysis by Indication, 2022-2026 Figure 97: Oceania Market Analysis by Distribution Channel –2022 & 2026 Figure 98: Oceania Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026 Figure 99: Oceania Market Attractiveness Analysis by Distribution Channel, 2022-2026 Figure 100: MEA Market Size (US$ Mn), 2015-2021 Figure 101: MEA Market Size (US$) & Y-o-Y Growth (%), 2022–2026 Figure 102: MEA Market Analysis by Country – 2022 & 2026 Figure 103: MEA Market Y-o-Y Growth Projections by Country, 2022-2026 Figure 104: MEA Market Attractiveness Analysis by Country, 2022-2026 Figure 105: MEA Market Analysis by Drug Type –2022 & 2026 Figure 106: MEA Market Y-o-Y Growth Projections by Drug Type, 2022-2026 Figure 107: MEA Market Attractiveness Analysis by Drug Type, 2022-2026 Figure 108: MEA Market Analysis by Indication –2022 & 2026 Figure 109: MEA Market Y-o-Y Growth Projections by Indication, 2022-2026 Figure 110: MEA Market Attractiveness Analysis by Indication, 2022-2026 Figure 111: MEA Market Analysis by Distribution Channel –2022 & 2026 Figure 112: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026 Figure 113: MEA Market Attractiveness Analysis by Distribution Channel, 2022-2026
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
